153 related articles for article (PubMed ID: 26759984)
1. Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia: An Analysis of SEER-Medicare Data From 1995 to 2007.
Lin PJ; Winn AN; Parsons SK; Neumann PJ; Weiss ES; Cohen JT
Med Care; 2016 Apr; 54(4):380-5. PubMed ID: 26759984
[TBL] [Abstract][Full Text] [Related]
2. The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.
Seymour EK; Ruterbusch JJ; Winn AN; George JA; Beebe-Dimmer JL; Schiffer CA
Cancer; 2021 Jan; 127(1):93-102. PubMed ID: 33119175
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leukaemia: a population-based analysis.
Menzin J; Lang K; Earle CC; Glendenning A
Drugs Aging; 2004; 21(11):737-46. PubMed ID: 15323579
[TBL] [Abstract][Full Text] [Related]
4. Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis.
Brunner AM; Campigotto F; Sadrzadeh H; Drapkin BJ; Chen YB; Neuberg DS; Fathi AT
Cancer; 2013 Jul; 119(14):2620-9. PubMed ID: 23625575
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
Warren E; Ward S; Gordois A; Scuffham P
Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Chemotherapy for Breast Cancer and Age Effect in Older Women.
Lairson DR; Parikh RC; Cormier JN; Chan W; Du XL
Value Health; 2015 Dec; 18(8):1070-8. PubMed ID: 26686793
[TBL] [Abstract][Full Text] [Related]
8. Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia.
Kenzik KM; Bhatia R; Williams GR; Bhatia S
Cancer; 2019 Aug; 125(15):2570-2578. PubMed ID: 30973642
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application.
Ghatnekar O; Hjalte F; Taylor M
Acta Oncol; 2010 Aug; 49(6):851-8. PubMed ID: 20615173
[TBL] [Abstract][Full Text] [Related]
10. Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data.
Lang K; McGarry LJ; Huang H; Dorer D; Kaufman E; Knopf K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):275-285.e1. PubMed ID: 27013180
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase.
Jabbour EJ; Lin J; Siegartel LR; Lingohr-Smith M; Menges B; Makenbaeva D
J Med Econ; 2017 Sep; 20(9):1007-1012. PubMed ID: 28681664
[TBL] [Abstract][Full Text] [Related]
12. Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data.
Danese MD; Reyes CM; Gleeson ML; Halperin M; Skettino SL; Mikhael J
Med Care; 2016 Apr; 54(4):343-9. PubMed ID: 26759977
[TBL] [Abstract][Full Text] [Related]
13. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
Winn AN; Keating NL; Dusetzina SB
J Clin Oncol; 2016 Dec; 34(36):4323-4328. PubMed ID: 27998234
[TBL] [Abstract][Full Text] [Related]
14. The value of medical spending in the United States, 1960-2000.
Cutler DM; Rosen AB; Vijan S
N Engl J Med; 2006 Aug; 355(9):920-7. PubMed ID: 16943404
[TBL] [Abstract][Full Text] [Related]
15. New Anticancer Drugs Associated With Large Increases In Costs And Life Expectancy.
Howard DH; Chernew ME; Abdelgawad T; Smith GL; Sollano J; Grabowski DC
Health Aff (Millwood); 2016 Sep; 35(9):1581-7. PubMed ID: 27605636
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP).
Chen Z; Wang C; Xu X; Feng W
Value Health; 2009; 12 Suppl 3():S85-8. PubMed ID: 20586990
[TBL] [Abstract][Full Text] [Related]
17. Systematic assessment of decision-analytic models for chronic myeloid leukemia.
Rochau U; Schwarzer R; Jahn B; Sroczynski G; Kluibenschaedl M; Wolf D; Radich J; Brixner D; Gastl G; Siebert U
Appl Health Econ Health Policy; 2014 Apr; 12(2):103-15. PubMed ID: 24385259
[TBL] [Abstract][Full Text] [Related]
18. Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study.
Perry AM; Brunner AM; Zou T; McGregor KL; Amrein PC; Hobbs GS; Ballen KK; Neuberg DS; Fathi AT
Cancer; 2017 Jul; 123(13):2561-2569. PubMed ID: 28464280
[TBL] [Abstract][Full Text] [Related]
19. The value of new chemotherapeutic agents for metastatic colorectal cancer.
Howard DH; Kauh J; Lipscomb J
Arch Intern Med; 2010 Mar; 170(6):537-42. PubMed ID: 20233802
[TBL] [Abstract][Full Text] [Related]
20. Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America.
Karalexi MA; Baka M; Ryzhov A; Zborovskaya A; Dimitrova N; Zivkovic S; Eser S; Antunes L; Sekerija M; Zagar T; Bastos J; Demetriou A; Agius D; Florea M; Coza D; Polychronopoulou S; Stiakaki E; Moschovi M; Hatzipantelis E; Kourti M; Graphakos S; Pombo-de-Oliveira MS; Adami HO; Petridou ET
Eur J Cancer; 2016 Nov; 67():183-190. PubMed ID: 27677054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
